U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H27N3O7.ClH
Molecular Weight 493.937
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MINOCYCLINE HYDROCHLORIDE

SMILES

Cl.[H][C@@]12CC3=C(C=CC(O)=C3C(=O)C1=C(O)[C@]4(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]4([H])C2)N(C)C

InChI

InChIKey=GLMUAFMGXXHGLU-VQAITOIOSA-N
InChI=1S/C23H27N3O7.ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32);1H/t9-,11-,17-,23-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C23H27N3O7
Molecular Weight 457.4764
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Minocycline is a tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. Minocycline has many brand names one of them is minocin, Minocin is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci etc. Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species etc. MINOCIN also is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection, etc. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Meningitis due to Neisseria meningitidis. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue, etc. Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Minocycline inhibits protein synthesis by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.7088001E10
Curative
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.7088001E10
Curative
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.7088001E10
Curative
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.7088001E10
Curative
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.7088001E10
Primary
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.7088001E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.63 μg/mL
135 mg 1 times / day steady-state, oral
dose: 135 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MINOCYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33.32 μg × h/mL
135 mg 1 times / day steady-state, oral
dose: 135 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MINOCYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
PubMed

PubMed

TitleDatePubMed
Minocycline and benign intracranial hypertension.
1992
Minocycline-induced autoimmune syndromes: an overview.
1999 Jun
Complications of minocycline therapy for acne vulgaris: case reports and review of the literature.
1999 Nov-Dec
Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine.
2000 Nov
Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.
2000 Oct
Giant cell myocarditis as a manifestation of drug hypersensitivity.
2000 Sep-Oct
Minocycline-associated lupus-like syndrome with ulnar neuropathy and antiphospholipid antibody.
2001
Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris.
2001 Feb
Minocycline hypersensitivity syndrome with hypotension mimicking septic shock.
2001 Jul-Aug
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons.
2001 Nov 23
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
2002 Mar
Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury.
2003 Oct
Severe acute myopathy induced by minocycline.
2004 Feb 15
Drug-induced liver injury.
2004 Mar 1
Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.
2004 Mar 3
Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures.
2004 Nov
Minocycline in neurological diseases.
2005 Mar
Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage.
2005 May 17
Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine.
2006 Dec 30
Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells.
2007 Nov
Patents

Sample Use Guides

For Pediatric Patients above 8 years of Age: usual pediatric dose: Initial dose of 4 mg/kg, then 2 mg/kg administered over 60 minutes every 12 hours, not to exceed the usual adult dose. Adults: usual adult dose: Initial dose of 200 mg, then 100 mg administered over 60 minutes ever y 12 hours and should not exceed 400 mg in 24 hours.
Route of Administration: Intravenous
It was investigated the minimal inhibitory concentration (MIC) of minocycline on superinfecting microorganisms isolated from the periodontal pocket and the oral cavity of individuals with chronic periodontitis. Isolates of Enterobacteriaceae (n = 25), Staphylococcus spp. (n = 25), Pseudomonas aeruginosa (n = 9) and Candida spp. (n = 25) were included in the study. Minimal inhibitory concentrations (MIC) of minocycline were determined using the Müeller-Hinton agar dilution method. Staphylococcus spp. isolates were the most sensitive to minocycline with a MIC of 8 microg/mL, followed by Enterobacteriaceae with a MIC of 16 microg/mL. The concentration of 16 microg/mL inhibited 96% of Candida spp. isolates. The MIC for 88.8% of the isolates of Pseudomonas aeruginosa was 128 microg/mL. A concentration of 1,000 microg/mL was not enough to inhibit 100% of the tested isolates.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:49:10 UTC 2023
Edited
by admin
on Wed Jul 05 22:49:10 UTC 2023
Record UNII
0020414E5U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MINOCYCLINE HYDROCHLORIDE
MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Common Name English
MINOCIN
Brand Name English
MINOCYCLINE HYDROCHLORIDE [MI]
Common Name English
ARESTIN
Brand Name English
Minocycline hydrochloride [WHO-DD]
Common Name English
SOLODYN
Brand Name English
NSC-141993
Code English
MINOCYCLINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
DYNACIN
Brand Name English
MINOCYCLINE HYDROCHLORIDE [VANDF]
Common Name English
MINOLIRA
Brand Name English
AMZEEQ
Brand Name English
MINOCYCLINE HYDROCHLORIDE [USP-RS]
Common Name English
MINOCYCLINE HYDROCHLORIDE [MART.]
Common Name English
ZILXI
Brand Name English
XIMINO
Brand Name English
MINOCYCLINE HCL
Common Name English
2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, MONOHYDROCHLORIDE, (4S-(4.ALPHA.,4A.ALPHA.,5A.ALPHA.,12A.ALPHA.))-
Common Name English
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride
Common Name English
MINOCYCLINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
MINOCYCLINE (AS HYDROCHLORIDE)
Common Name English
MINOCYCLINE HYDROCHLORIDE [JAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 213305
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
NCI_THESAURUS C1595
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
FDA ORPHAN DRUG 67092
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
237-099-7
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
DAILYMED
0020414E5U
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
CHEBI
50697
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
SMS_ID
100000091841
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
EPA CompTox
DTXSID8044545
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
EVMPD
SUB03304MIG
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
RXCUI
6979
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY RxNorm
RS_ITEM_NUM
1444004
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
MERCK INDEX
M7553
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C47622
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
NSC
141993
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
FDA UNII
0020414E5U
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
CAS
13614-98-7
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
ChEMBL
CHEMBL1434
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
DRUG BANK
DBSALT000721
Created by admin on Wed Jul 05 22:49:10 UTC 2023 , Edited by admin on Wed Jul 05 22:49:10 UTC 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY